Predictability of response and compatibilty of systemic therapy using the Maximum Liver Function Capacity (LiMAx) test in patients with hepatocellular carcinoma (HCC)
Recruiting
- Conditions
- C22Malignant neoplasm of liver and intrahepatic bile ducts
- Registration Number
- DRKS00018886
- Lead Sponsor
- niversitätsklinikum Leipzig AöR, Klinik und Poliklinik für Gastroenterologie, Hepatologie, Infektiologie, Pneumologie, Sektion Hepatologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients (m / f) = 18 years with HCC and indication for systemic treatment as determined by the responsible tumor board
- written consent of the participating patients
- No contraindications for performing a LiMAx test
Exclusion Criteria
- no written consent of the participating patients
- contraindications for performing a LiMAx test
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predictability of response and compatibilty of systemic therapy of HCC using LiMAx test
- Secondary Outcome Measures
Name Time Method 1) Correlation of the results of the LiMAx test with the Child-Pugh score in patients with HCC<br><br>2) extent of decrease or regeneration of liver function after systemic therapy according to LiMAx test<br><br>3) Comparison of the results of the LiMAx test with the ART score regarding the prognostic relevance